Natural fulvic acids inhibit non-small-cell lung cancer through the COX-2/PGE2/EP4 axis: In silico and in vivo assessments

被引:2
作者
Xin, Pengfei [1 ,2 ]
Wang, Shirui [3 ]
Xu, Xin [3 ]
Liu, Qingmei [1 ,2 ]
Zhang, Caifeng [4 ]
机构
[1] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3, Taiyuan 030032, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
[3] Shanxi Med Univ, Sch & Hosp Stomatol, Taiyuan 030001, Peoples R China
[4] Taiyuan Normal Univ, Hum Acid Engn & Technol Res Ctr Shanxi Prov, Dept Chem, Jinzhong 030619, Peoples R China
关键词
Fulvic acids; Humic acids; Non -small -cell lung cancer; Molecular docking; EP4; HUMIC SUBSTANCES; EXPRESSION; REVEALS; GROWTH;
D O I
10.1016/j.heliyon.2023.e17080
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Non-small-cell lung cancer (NSCLC) is a major public health concern with a high inci-dence worldwide. Coal-derived fulvic acids (FAs) contain functional groups in their chemical structures. Overexpression of cyclooxygenases-2 (COX-2), prostaglandin E2 (PGE2), and the PGE2 receptor EP4 subtype (EP4) can have a potential link with the increased tumor incidence and promoted tumor growth and metastasis in NSCLC. This study aimed to assess the biological roles of coal-derived FAs in the growth and development of NSCLC and to elucidate the underlying molecular mechanisms.Methods: A web-based tool for predicting small-molecule pharmacokinetics (pkCSM) was used to analyze the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of FAs. Molecular docking and dynamic simulations were performed to analyze the binding affinities of COX-2 and EP4 to FA. An acute toxicity test and an antitumor study were used to analyze the toxicity and anti-NSCLC effects of FAs. Thirty NSCLC-bearing nude mice were randomly divided into five groups (six mice per group): vehicle control, positive control with 20 mg/kg body weight (BW) 5-fluorouracil, and three treatments with 25, 50, and 100 mg/kg BW FAs. The BW and tumor volume were recorded, and the COX-2, PGE2, and EP4 protein expression were measured and analyzed.Results: Using the predictive pkCSM algorithm, we found that FA did not cause developmental toxicity. Molecular simulations revealed that COX-2 and EP4 expression was inhibited by FA. An acute toxicity test conformed that the maximum tolerated FAs dose was >3.0 g/kg BW. The
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGE2 pathway in non-small cell lung cancer
    Zhao, Minghui
    Wang, Yiwei
    Zhao, Yucui
    He, Sijia
    Zhao, Ruyi
    Song, Yanwei
    Cheng, Jin
    Gong, Yanping
    Xie, Jianzhu
    Wang, Yulan
    Hu, Binjie
    Tian, Ling
    Huang, Qian
    AGING-US, 2020, 12 (21): : 21758 - 21776
  • [22] Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis
    Yi, Ouyang
    Zhong, Wenlong
    Xu, Peiqi
    Wang, Bo
    Zhang, Lin
    Yang, Meng
    Chen, Junyu
    Li, Hong
    Li, Sheng
    Chen, Xiang
    Xu, Longhao
    Ou, Ziwei
    Wu, Daqin
    Lin, Yi
    Wang, Chunhui
    Huang, Jian
    Lin, Tianxin
    BRITISH JOURNAL OF CANCER, 2024, 130 (05) : 880 - 891
  • [23] The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
    Zhou, Fei
    Gao, Guanghui
    Ren, Shengxiang
    Li, Xuefei
    He, Yayi
    Zhou, Caicun
    PLOS ONE, 2013, 8 (04):
  • [24] COX-2 Expression Does Not Predict Outcome of Celecoxib in Addition to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Gulyas, Miklos
    Mattsson, Johanna S. M.
    Lindgren, Andrea
    Sederholm, Christer
    Ek, Lars
    Lamberg, Kristina
    Behndig, Annelie
    Holmberg, Erik
    Micke, Patrick
    Bergman, Bengt
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S541 - S542
  • [25] AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway
    Zhang, Minda
    Jin, Chenyu
    Yang, Yunjia
    Wang, Keke
    Zhou, Yunjiang
    Zhou, Yang
    Wang, Rui
    Li, Tao
    Hu, Rong
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (11) : 20161 - 20173
  • [26] Resistance to ursolic acid-induced apoptosis through involvement of melanogenesis and COX-2/PGE2 pathways in human M4Beu melanoma cancer cells
    Hassan, Lama
    Pinon, Aline
    Limami, Youness
    Seeman, Josiane
    Fidanzi-Dugas, Chloe
    Martin, Frederique
    Badran, Bassam
    Simon, Alain
    Liagre, Bertrand
    EXPERIMENTAL CELL RESEARCH, 2016, 345 (01) : 60 - 69
  • [27] microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2
    Gao, Jie
    Feng, Xiaojing
    Wang, Fang
    Wang, Junlan
    Wang, Hongmei
    Li, Hua
    Zhang, Weiwei
    Hao, Lijun
    Shi, Zhiming
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (08) : 13453 - 13463
  • [28] COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
    Gulyas, Miklos
    Mattsson, Johanna Sofia Margareta
    Lindgren, Andrea
    Ek, Lars
    Lundstrom, Kristina Lamberg
    Behndig, Annelie
    Holmberg, Erik
    Micke, Patrick
    Bergman, Bengt
    ACTA ONCOLOGICA, 2018, 57 (02) : 244 - 250
  • [29] KCNAB2 overexpression inhibits human non-small-cell lung cancer cell growth in vitro and in vivo
    Cheng, Feng
    Tang, Yu-fei
    Cao, Yang
    Peng, Shi-qing
    Zhu, Xiao-ren
    Sun, Yue
    Wang, Shu-Hang
    Wang, Bin
    Lu, Yi-min
    CELL DEATH DISCOVERY, 2023, 9 (01)
  • [30] MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
    Yang, Yang
    Qiu, Rongfang
    Weng, Qiaoyou
    Xu, Ziwei
    Song, Jingjing
    Zhao, Siyu
    Meng, Miaomiao
    Zhang, Dengke
    Kong, Chunli
    Wang, Hailin
    Xu, Min
    Zhao, Zhongwei
    Ji, Jiansong
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 778 - 803